CTNNB1 and neoplasm: Remarkably, following continued once weekly I.V. administration at 1mg/kg dosage over 6 weeks, there was a decrease in gross tumor burden (Figure 1h–l), and also a significant tumor response observed via H&E, Myc-tag, and GS/Ki67 IHC following LNP-CTNNB1 treatment (Figure 1l; Figure S3e–f).